Life Science Connect
Life Science ConnectEpisodes
Episodes of Life Science Connect
Mark All
Search Episodes...
Diversity & inclusion is — and has been — an important issue for the biopharmaceutical industry. As such, we thought it would be worthwhile to gain some perspective.
Considering many Life Science Leader readers daydream of starting and leading their own biopharmaceutical company someday, we thought it would be informative to host an executive virtual roundtable with three biopharmaceutical company CEOs who
Fundraising used to always be done in person. But then COVID hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have actually become quite proficient at the process and the platforms. Three bioph
According to Outsourced Pharma Chief Editor, Louis Garguilo, “politics has never played a bigger role in our (global) biopharma industry.” In this episode, we talk with Louis about three of his recent editorials that touch on this subject while
We thought it would be interesting to have a discussion with three biopharmaceutical executives about how they are preparing for this unique 2021 JPM and how those preparations are different than what they’ve done in the past.
We sat down with three biopharmaceutical industry executives to discuss some of the thinking and actions taken to mitigate risk to their companies’ manufacturing and supply chains amidst a pandemic.
Three biopharmaceutical industry VPs of HR departments discuss the challenges of continued operations amidst COVID-19 initiated lockdowns, along with some of the best practices implemented.
Erin Harris, chief editor of cellandgene.com explains what makes cell and gene therapy manufacturing more complex what some of the current hurdles and bottlenecks are that companies in this sector of life sciences face.
Pamela Contag, Ph.D., cofounder and CEO of BioEclipse Therapeutics, a clinical-stage oncology company; and Dara Lockert, founder and executive director of Spannerwerks, a life science industry consultancy, share best practices and lessons learn
Four biopharmaceutical industry CEOs and company cofounders converse on what their organizations are doing to spur the development of diagnostic tests, therapeutics, and vaccines in order to turn the tide on the COVID-19 pandemic.
Four biopharma CEOs discuss with Rob Wright, chief editor of Life Science Leader, how they are leading their organizations and conducting drug development during the COVID-19 pandemic.
Three CEOs of publicly traded biopharmaceutical companies discuss how they are leading their organizations, while also managing the expectations of Wall St. during the COVID-19 pandemic.
Five biopharmaceutical industry CEOs discuss challenges their companies have faced, along with best practices implemented in managing through the COVID-19 chaos.
Starting in April 2021, each week we will be releasing the audio portion of various episodes of our popular Executive Virtual Roundtables (EVRs). In them, we cover topics such as leadership and drug development during COVID, how to accelerate a
BioProcess Online Chief Editor, Matt Pillar, discusses the current vaccine market, some advancements that have been made, and if its growth is sustainable.
Will decentralized clinical trials continue to be a hot topic even after the pandemic or will pharma companies revert to their old ways. Our guest, ClinicalLeader.com Chief Editor, Ed Miseta, weighs in on this timely topic.
Life Science Leader Chief Editor Rob Wright has attended numerous JPM conferences, so he gives his feedback on how this year’s virtual show compared to previous years.
Erin Harris, Chief Editor of cellandgene.com, reviews some of the hot cell and gene therapy topics for 2020 and what to watch for in 2021. She also discusses the upcoming Cell & Gene Live! event and the miniseries she did for the Business of Bi
2020 seems to be the year of the evolution of the atypical, newfangled CDMO. Outsourced Pharma Chief Editor Louis Garguilo talks about this trend and what makes these new models all the rage.
Today’s guest, Matt Pillar, not only hosts two of his own podcasts, but is our Chief Editor for BioProcess Online. Matt gives a peek into what trends he wrote about for the Life Science Leader outlook issue, and he talks about what’s next for h
It was only a little more than a year ago when the phrase “throw in the towel” was being used in reference to the biosimilars industry. Now, some say we’re in the “Golden Age” of biosimilars. Biosimilar Development Chief Editor, Anna Rose Welch
Our guest, Outsourced Pharma Chief Editor Louis Garguilo, talks about the response from readers — and PhRMA — to his editorial, “Is PhRMA’s White House Rebuttal Acceptable?”
Ever wonder how a pharma executive gets to be on the cover of Life Science Leader? For Tim Wright, CEO of MiMedx, it was a chance encounter at a leadership conference a few years ago.
Outsourced Pharma Chief Editor Louis Garguilo elaborates on his recent editorial regarding the immense opportunity that Puerto Rico offers —and has offered for years — pharma manufacturers looking to bring back operations to the states.
Anna Rose Welch talks about a new whitepaper that explains why now is the best time for a U.S. biosimilars shared savings model.
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us